PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today that it has received Institutional Review Board (IRB) approval from six sites within the United States targeted to participate in its Phase II clinical trial which will evaluate the preliminary safety and efficacy of topical Dermacyn® Wound Care versus systemic oral antibiotics for the treatment of mild diabetic foot infections. Dermacyn is a non-irritating solution containing oxychlorine compounds manufactured using Oculus’ proprietary Microcyn® Technology.
